Recent patent trends in the field of progesterone receptor agonists and modulators

Norbert Schmees, Hilmar Weinmann
Expert opinion on therapeutic patents · 2009 · vol. 19(11) , pp. 1521–1534 · doi:10.1517/13543770903312946 · PMID:19785507 · W2122427605
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher

Abstract

BACKGROUND: Progesterone receptor agonists are used in female contraception, hormone replacement therapy or some gynecological conditions like endometriosis. The interest for antagonists or selective progesterone receptor modulators (SPRMs) is growing. Recent reports on this class of compounds indicate that they could become the next generation of therapeutics in gynecological treatments. OBJECTIVE: This overview summarizes the work on progesterone receptor agonists, SPRMs and antagonists reported in the patent literature in the past 4 years. METHODS: The focus of the article is the examination of patents, primarily published as WO, EU or US patents since 2005. In some cases, additional data from the public literature is included into the discussion. These data are of substantial interest as the available biological data disclosed in patents are usually limited for new compound classes. RESULTS/CONCLUSION: Some highly active clusters of compounds have been disclosed in the past 4 years. The current research seems to focus on SPRMs and progesterone receptor antagonists.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Receptors, Progesterone Receptors, Progesterone Animals Contraceptive Agents, Female Contraceptive Agents, Female Drug Design Endometriosis Endometriosis Endometriosis Female Hormone Replacement Therapy Hormone Replacement Therapy Humans Male Patents as Topic Receptors, Progesterone Receptors, Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (53)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:13:59.677786+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK